Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery
Grossman SA, Romo CG, Rudek MA, Supko J, Fisher J, Nabors LB, Wen PY, Peereboom DM, Ellingson BM, Elmquist W, Barker FG, Kamson D, Sarkaria JN, Timmer W, Bindra RS, Ye X. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery. Neuro-Oncology 2020, 22: 1422-1424. PMID: 32506123, PMCID: PMC7566550, DOI: 10.1093/neuonc/noaa142.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrain NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDrug Delivery SystemsHumansPharmaceutical Preparations